Form 4: Editas Medicine EVP Erick Lucera Sells Shares to Cover Tax Obligations

EVP and CFO of Editas Medicine, Erick Lucera, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Erick Lucera, the EVP and CFO of Editas Medicine, sold 22,337 shares of common stock on May 20, 2024.
• The sale was executed at a price of $5.6142 per share.
• The transaction was conducted automatically under a pre-arranged sales plan adopted on May 12, 2023.
• The sale was necessary to cover tax withholding obligations resulting from the vesting of restricted stock units on May 17, 2024.
• Following the transaction, Lucera directly owns 116,829 shares of Editas Medicine common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale to cover tax obligations and doesn't necessarily reflect a change in the executive's confidence in the company.

Positives

• The sale was conducted under a pre-arranged plan, indicating it was not based on current market sentiment or inside information.

Management Comments

• The sale does not represent a discretionary trade by the Reporting Person.

Industry Context

Sales of shares to cover tax obligations are a common practice among executives who receive equity compensation. This transaction is not necessarily indicative of the executive's view of the company's future prospects.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a common occurrence across the biotechnology industry.
• Companies like CRISPR Therapeutics and Intellia Therapeutics also see similar transactions from their executives.
• The volume of shares sold is relatively small compared to the total outstanding shares of Editas Medicine.

Stakeholder Impact

• The sale may have a minor impact on shareholders due to the small volume of shares involved.

Key Dates